全文获取类型
收费全文 | 20248篇 |
免费 | 1167篇 |
国内免费 | 156篇 |
专业分类
耳鼻咽喉 | 227篇 |
儿科学 | 538篇 |
妇产科学 | 688篇 |
基础医学 | 2235篇 |
口腔科学 | 571篇 |
临床医学 | 1672篇 |
内科学 | 4031篇 |
皮肤病学 | 403篇 |
神经病学 | 958篇 |
特种医学 | 757篇 |
外国民族医学 | 11篇 |
外科学 | 3509篇 |
综合类 | 396篇 |
现状与发展 | 2篇 |
一般理论 | 13篇 |
预防医学 | 1800篇 |
眼科学 | 588篇 |
药学 | 1828篇 |
中国医学 | 152篇 |
肿瘤学 | 1192篇 |
出版年
2024年 | 19篇 |
2023年 | 280篇 |
2022年 | 848篇 |
2021年 | 1223篇 |
2020年 | 666篇 |
2019年 | 807篇 |
2018年 | 1096篇 |
2017年 | 638篇 |
2016年 | 672篇 |
2015年 | 687篇 |
2014年 | 944篇 |
2013年 | 1101篇 |
2012年 | 1607篇 |
2011年 | 1770篇 |
2010年 | 1002篇 |
2009年 | 729篇 |
2008年 | 1012篇 |
2007年 | 1028篇 |
2006年 | 926篇 |
2005年 | 892篇 |
2004年 | 773篇 |
2003年 | 706篇 |
2002年 | 634篇 |
2001年 | 144篇 |
2000年 | 119篇 |
1999年 | 104篇 |
1998年 | 82篇 |
1997年 | 74篇 |
1996年 | 76篇 |
1995年 | 68篇 |
1994年 | 60篇 |
1993年 | 54篇 |
1992年 | 51篇 |
1991年 | 56篇 |
1990年 | 56篇 |
1989年 | 48篇 |
1988年 | 54篇 |
1987年 | 50篇 |
1986年 | 41篇 |
1985年 | 41篇 |
1984年 | 40篇 |
1983年 | 36篇 |
1982年 | 34篇 |
1981年 | 23篇 |
1980年 | 22篇 |
1978年 | 16篇 |
1977年 | 14篇 |
1976年 | 17篇 |
1974年 | 13篇 |
1973年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Abdelaal M. Elkamshoushi Noha M. Badae Mohamed G. Kabary Shaimaa I. Omar 《Andrologia》2021,53(1):e13833
Avanafil is a highly selective and potent oral phosphodiesterase type 5 inhibitor. However, its impact on the soluble markers of endothelial function has not been investigated yet. This study was conducted to assess the effect of daily avanafil on the endothelial markers' serum level and erectile function in patients with erectile dysfunction. In this work, we randomly divided 140 males with erectile dysfunction and other diseases commonly associated with endothelial dysfunction like diabetes mellitus, hypertension and dyslipidaemia into two equal groups: treatment group, treated with 50mg daily oral avanafil, and control group, treated with placebo. The International Index of Erectile Function-5 score and the serum levels of nitric oxide, cyclic guanosine monophosphate and endothelin-1 as markers of endothelial function were measured at baseline and after four weeks of treatment in both groups. At the end of treatment period, those randomised to avanafil achieved statistically significant improvement in erectile function, nitric oxide, cyclic guanosine monophosphate and endothelin-1 levels from baseline versus placebo regardless the type and duration of associated comorbidity as well as the duration and severity of erectile dysfunction. These results permitted us to suggest that daily avanafil can improve the impaired endothelial function associated with the erectile dysfunction. 相似文献
62.
Haitham Elbardisi Ahmad Majzoub Christiana Daniel Fadwa Al.Ali Mohamed Elesnawi Kareim Khalafalla Ashok Agarwal Ralf Henkel Alia Alattar Ibrahim Al-Emadi Mohamed Arafa 《Andrologia》2021,53(8):e14135
In this study, we investigated the prevalence of sexual dysfunction among males with advanced chronic kidney disease and the effect of treating hyperprolactinemia among these patients. In this prospective study, patients were assessed with history, physical examination, hormonal assessment, and two questionnaires, IIEF and AIPE. Patients with hyperprolactinemia received treatment with cabergoline 0.5 mg once per week for 6 months and were re-evaluated. A total of 102 patients were included in this study, 75 (73.53%) were on hemodialysis, 13 (12.75%) on peritoneal dialysis and 14 (13.73%) on medical treatment alone. Ninety (88.24%) patients had premature ejaculation, 85 (83.33%) had anything from mild-to-moderate-to-severe erectile dysfunction. The incidence of hypogonadism and hyperprolactinemia was 34.4%. Patients treated with cabergoline (n = 26) showed a significant increase in LH levels (p = .003) and a significant decrease in prolactin levels (p = .003). Testosterone levels and the incidence of erectile dysfunction or premature ejaculation did not improve significantly. There is a high incidence of sexual dysfunction among patients. Treatment of hyperprolactinemia is effective in correcting prolactin levels, but does not improve erectile dysfunction or premature ejaculation. Therefore, treating hyperprolactinemia is not an overall effective treatment for erectile dysfunction in these patients. 相似文献
63.
64.
Sean Z. Griffiths Mohamed F. Albana Lauryn D. Bianco Manuel C. Pontes Eddie S. Wu 《The Journal of arthroplasty》2021,36(3):946-952
BackgroundThe use of robotic-assisted total knee arthroplasty (TKA) has significantly increased over the past decade. Internet content is largely unregulated and may contain inaccurate and/or misleading information about robotic TKA. Our goal was to assess the content, quality, and readability of online material regarding robotic-assisted TKA.MethodsWe conducted an internet search for the top 50 web sites from each of the 3 most popular search engines (Google, Yahoo, and Bing) using the search term robotic total knee replacement. Each web site was assessed for content, quality, and readability. Web site quality was assessed utilizing the QUality Evaluation Scoring Tool (QUEST). Readability was assessed utilizing the Simple Measure of Gobbledygook, Flesch-Kincaid Grade Level, and Flesch Reading Ease Formula scores.ResultsGeneral risks of TKA were discussed in 47.2%, while benefits were discussed in 98.6% of all web sites. Inaccurate claims occurred at a significantly higher rate in physician/community hospital sources compared to university/academic web sites (59% vs 28%, P = .045). Web sites from university/academic web sites had the highest QUEST scores, while physician/community hospital sources scored the lowest (16.1 vs 10.6, P = .01). Most web sites were written at a college reading level or higher.ConclusionPatients should be counseled on the largely unregulated nature of online information regarding robotic-assisted TKA. Physicians and hospitals should consider revising the readability of their online information to a more appropriate level in order to provide accurate, evidence-based information to allow the patient to make an informed consent decision. 相似文献
65.
David K. C. Cooper Hidetaka Hara Hayato Iwase Takayuki Yamamoto Zheng‐Yu Wang Abhijit Jagdale Mohamed H. Bikhet Huy Q. Nguyen Jeremy B. Foote Wayne D. Paris David Ayares Vineeta Kumar Douglas J. Anderson Jayme E. Locke Devin E. Eckhoff 《Clinical transplantation》2021,35(1):e14139
Pig organ xenotransplantation offers a solution to the shortage of deceased human organs for transplantation. The pathobiological response to a pig xenograft is complex, involving antibody, complement, coagulation, inflammatory, and cellular responses. To overcome these barriers, genetic manipulation of the organ‐source pigs has largely been directed to two major aims—(a) deletion of expression of the known carbohydrate xenoantigens against which humans have natural (preformed) antibodies, and (b) transgenic expression of human protective proteins, for example, complement‐ and coagulation‐regulatory proteins. Conventional (FDA‐approved) immunosuppressive therapy is unsuccessful in preventing an adaptive immune response to pig cells, but blockade of the CD40:CD154 costimulation pathway is successful. Survival of genetically engineered pig kidneys in immunosuppressed nonhuman primates can now be measured in months. Non‐immunological aspects, for example, pig renal function, a hypovolemia syndrome, and rapid growth of the pig kidney after transplantation, are briefly discussed. We suggest that patients on the wait‐list for a deceased human kidney graft who are unlikely to receive one due to long waiting times are those for whom kidney xenotransplantation might first be considered. The potential risk of infection, public attitudes to xenotransplantation, and ethical, regulatory, and financial aspects are briefly addressed. 相似文献
66.
67.
Jonathan J. Hue Kavin Sugumar Sarah C. Markt Amr Mohamed J. Eva Selfridge David Bajor Luke D. Rothermel Jeffrey M. Hardacre John B. Ammori Jordan M. Winter Lee M. Ocuin 《Surgery》2021,169(2):233-239
BackgroundMost data on postoperative outcomes among patients with proximal extrahepatic cholangiocarcinoma are reported by single institutions. The purpose of this study was to analyze postoperative outcomes stratified by age and comorbidities.MethodsPatients with proximal extrahepatic cholangiocarcinoma who underwent a resection were identified in the National Cancer Database. Pathologic, postoperative, and survival outcomes were compared based on age and Charlson-Deyo comorbidity index.ResultsAmong the 1,579 patients, the average age was 66 years, and 9.4% of patients were older than 80 years. Most patients had a Charlson-Deyo score of 0 (72.4%), with the minority having scores of 1 (20.5%) or ≥2 (7.1%). Patients ≥80 years had a higher 90-day mortality rate compared with patients 65 to 79 and <65 years (21.3% vs 12.0% vs 7.4%, P < .001). Patients with a Charlson-Deyo score ≥2 had longer duration of stay, greater likelihood of requiring an unplanned readmission, and a higher 90-day mortality rate compared with patients with a lower comorbidity index. Median survival of patients <65, 65 to 79, and ≥80 years was 31, 24, and 17 months, respectively. A similar trend was seen with increasing Charlson-Deyo score (0: 27 months, 1: 25 months, ≥2: 20 months). On multivariable analysis, age ≥80 years (hazard ratio = 1.52, P = .01) and Charlson-Deyo score ≥2 (hazard ratio = 1.45, P = .01) were associated with poor survival.ConclusionIn patients with proximal extrahepatic cholangiocarcinoma, age ≥80 years and greater comorbidity index are associated with increased risk of 90-day mortality and poor overall survival. This suggests that resections in high-risk patient populations should be approached with caution. 相似文献
68.
69.
Aurore Prunevieille Mohamed H. Babiker-Mohamed Colleen Aslami Bruno Gonzalez-Nolasco Nuala Mooney Gilles Benichou 《American journal of transplantation》2021,21(7):2583-2589
Extracellular vesicles, including exosomes, are regularly released by allogeneic cells after transplantation. Recipient antigen-presenting cells (APCs) capture these vesicles and subsequently display donor MHC molecules on their surface. Recent evidence suggests that activation of alloreactive T cells by the so-called cross-dressed APCs plays an important role in initiating the alloresponse associated with allograft rejection. On the other hand, whether allogeneic exosomes can bind to T cells on their own and activate them remains unclear. In this study, we showed that allogeneic exosomes can bind to T cells but do not stimulate them in vitro unless they are cultured with APCs. On the other hand, allogeneic exosomes activate T cells in vivo and sensitize mice to alloantigens but only when delivered in an inflammatory environment. 相似文献
70.
Dalia O. Mohamed Mona M. Sayed Islam F. Abdelkawi Mahmoud H. Elshoieby Salah M. Khallaf Lamia M. Khallaf Doaa M. Fouad 《Current Urology》2021,15(1):11
Background:Randomizing patients to bladder preservation or radical cystectomy (RC) for the treatment of bladder cancer has not been practical, due to patient and physician preferences. Therefore, continually comparing the 2 treatment modalities is needed, in order to make the proper choice for each patient.Patients and methods:The records of T1–4N0M0 bladder cancer patients, who presented to the South Egypt Cancer Institute between 2007 and 2017 and were treated by either bladder preservation or RC were reviewed.Results:Out of the 166 included patients, 81 (48.8%) patients were treated by bladder preservation and 85 (51.2%) patients had RC. For the patients treated by bladder preservation and the patients treated by RC, the 5-year overall survival (OS) was 56% and 60% (p = 0.67), the 5-year local recurrence-free survival was 69% and 73% (p = 0.69), and the 5-year disease-free survival was 45% and 53% (p = 0.16), respectively. After propensity matching analysis, the mean 5-year OS was 58% for the bladder preservation patients and 61% for the RC patients (p = 0.51). It is notable that among the bladder preservation group, 8 patients (10%) had squamous cell carcinoma (SCC) pathology and refused RC. Their OS was 56% compared to 53% for the SCC patients treated by RC (p = 0.6).Conclusion:Bladder preservation is a safe alternative to cystectomy in transitional cell carcinoma stages T1–4aN0M0, and its use in SCC bladder cancer should be further studied, as it could be feasible to spare them from initial cystectomy. 相似文献